The Sensory Organ Drugs market in Turkey is showing promising growth in recent years.
Customer preferences: The demand for sensory organ drugs in Turkey is driven by the increasing prevalence of sensory organ disorders, such as hearing loss, vision impairment, and balance disorders. The aging population in Turkey is also contributing to the growth of the market, as the risk of developing these disorders increases with age. Additionally, the growing awareness about the importance of early diagnosis and treatment of sensory organ disorders is driving the demand for these drugs.
Trends in the market: One of the major trends in the sensory organ drugs market in Turkey is the increasing use of innovative technologies and treatments. For instance, gene therapy is emerging as a potential treatment option for certain types of hearing loss and vision impairment. Additionally, the development of targeted therapies and personalized medicine is expected to drive the growth of the market in the coming years. Another trend in the market is the increasing focus on over-the-counter (OTC) drugs, which are more easily accessible to patients and do not require a prescription.
Local special circumstances: Turkey has a well-developed healthcare system, with both public and private healthcare facilities. The government has been taking steps to improve access to healthcare services, including the provision of free healthcare services to certain segments of the population. However, the healthcare system in Turkey faces challenges such as a shortage of healthcare professionals, particularly in rural areas, and inadequate funding for healthcare services.
Underlying macroeconomic factors: Turkey has a large and growing population, with a median age of 32 years. The country has a strong economy and is strategically located between Europe and Asia, making it an attractive market for international pharmaceutical companies. However, Turkey has been facing economic challenges in recent years, including high inflation and currency devaluation, which could impact the growth of the pharmaceutical industry in the country. Additionally, the COVID-19 pandemic has had a significant impact on the healthcare system in Turkey, with resources being redirected to manage the outbreak.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
